Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Digital Genome Market - Insights
Digital genome is one of the emerging technologies in DNA sequencing, which allows to perform human genome sequencing and digitalization in minutes and at the cost of only a few hundred dollars. This is specifically more efficient than the first sequencing of the 3.2 billion base pairs of a DNA that make up the human genome, which took many years and cost millions of dollars to be completely sequenced. Such continuous advancement in the field of digital genome enables to deliver rapid and cost-effective DNA sequencing for development of personalized medicine and clinical treatment.
The global digital genome market is estimated to be valued at US$ 7,594.8 million in 2018, and is expected to witness a CAGR of 10.9% during the forecast period (2018–2026).
Global Digital Genome Market Share (%), By Product Type: 2018 & 2026
Source: Coherent Market Insights Analysis (2018)
Increasing Technological Advancement in Digital Genome field is expected to augment the Market Growth
Increasing technological advancements and growing awareness related to use of genomes for diagnosis of diseases such as cancer, diabetes, and Attention Deficit Hyperactivity Disorder (ADHD) is expected to drive growth of the digital genome market. For instance, in February 2018, the National Human Genome Research Institute (NHGRI) launched a strategic planning, which will establish a 2020, vision for genomics research aimed at accelerating scientific and medical breakthroughs. Furthermore, in the development of this strategic planning, the institute will engage experts and diverse public communities to identify diverse areas of genomics, which will expand the novel applications in human health and disease treatments.
Furthermore, Artificial Intelligence and machine learning methods are currently been used to overcome various problems faced by genomics such as annotating genomic sequence elements, identifying splice sites, promoters, enhancers, and positioned nucleosomes. For instance, Sapientia: a clinical genomics analysis platform from Congenica, uses algorithms to annotate and priorities variants from whole-exome sequencing to assist in the diagnosis of rare diseases.
In December 2017, Google released DeepVariant: an Artificial Intelligence (AI) tool, which uses AI techniques to build more precise picture of any individual’s genome from sequencing data. DeepVariant automatically identifies small insertion and deletion mutations and single base-pair mutations in sequencing data.
In February 2018, the Canadian Genomics Cloud launched an advanced public cloud platform that allows researchers from Canada to securely store, share, and analyze genomics data for further discoveries.
Global Digital Genome Market Share (%), By Application: 2018 & 2026
Source: Coherent Market Insights Analysis (2018)
Increasing Adoption of Personalized Medicine is expected to propel the Market Growth
Increasing inclination towards use of genomes to predict reaction of medication for safe and effective treatment of cancer, Attention Deficit Hyperactivity Disorder (ADHD), and diabetes is expected to boost the market growth. Moreover, the need to choose the most appropriate treatment for ADHD and nutrition profiling where DNA is used to prevent development of chronic diseases is expected to be major growth factor for the digital genome market.
According to the World Health Organization (WHO), cancer is one of the leading causes of morbidity and mortality across the world, with around 14 million new cases reported worldwide in 2012. The World Health Organization (WHO) also suggests that 30-50% deaths caused due to cancer can be prevented by adequate treatment in early stages. In these scenario, personalized medicine offers most promising approaches to tackle diseases, which have far eluded effective treatments or cures.
Personalized medicine is an emerging approach for disease treatment and prevention, which takes into account individual variability in genes, environment, and lifestyle for each person. In September 2018, Congenica: a diagnostic decision support platform provider, entered into an agreement with Digital China Health Technologies Cooperation Limited (DCHealth) to introduce a genomic medicine in the Chinese market. In this partnership, Congenica will develop a version of its Sapientia platform that is designed to enable healthcare professionals and patients in China to benefit from the clinical genomics and personalized medicine. DCHealth will offer its significant commercial network and experience in the Chinese hospital market to accelerate the commercialization of this locally-adapted version of Sapientia.
Among regions, North America is expected to be the most attractive market for digital genome due to presence of key players in the region, which are majorly involved in gaining regulatory approvals and launch of digital genome-based products and technologies in this market. Increasing awareness regarding personalized medicines and its effectiveness in the targeted treatment of cancer and various other infectious diseases will generate high demand for digital genome technologies in near future.
Expanding healthcare infrastructure in emerging economies such as India and growing disease burden in these economies is contributing to growth of the digital genome market in Asia Pacific. For instance, in October 2017, Genome India Project was launched in the northeast region of India, which involves Whole Genome Sequencing (WGS) of over 2,000 individuals of different ethnic, linguistic, and social-cultural section of the northeastern states. This genetic information will be helpful in reducing disease burden by the application of personalized medicine.
Key players operating in the global digital genome market include, Illumina, Inc., PerkinElmer, Inc., Pacific Biosciences of California, Inc., Thermo Fisher Scientific Inc., Oxford Nanopore Technologies Limited, Nanostring Technologies, Inc., IBM Corporation, Google LLC, Amazon.com, Inc., Deep Genomics, Deep Genomics, Deep Genomics, Desktop Genetics Ltd., and Ancestry.com LLC.